See more : Molecular Data Inc. (MKDTY) Income Statement Analysis – Financial Results
Complete financial analysis of XTL Biopharmaceuticals Ltd. (XTLB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of XTL Biopharmaceuticals Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Daol Investment & Securities Co., Ltd. (030210.KS) Income Statement Analysis – Financial Results
- BiON plc (BION.L) Income Statement Analysis – Financial Results
- PT KDB Tifa Finance Tbk (TIFA.JK) Income Statement Analysis – Financial Results
- China CITIC Bank Corporation Limited (CHCJY) Income Statement Analysis – Financial Results
- Locksley Resources Limited (LKY.AX) Income Statement Analysis – Financial Results
XTL Biopharmaceuticals Ltd. (XTLB)
About XTL Biopharmaceuticals Ltd.
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | -459.00K | 1.47M | 28.00K | 69.00K | 52.00K | 29.00K | 23.00K | -6.00K | 41.00K | 2.37M | 938.00K | 0.00 | 0.00 | 0.00 | 5.94M | 907.00K | 454.00K | 3.20M | 3.45M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 1.00K | 1.00K | 1.00K | 0.00 | 0.00 | 1.00K | 3.00K | 7.00K | 17.00 | 741.00K | 380.00K | 0.00 | 0.00 | 0.00 | -5.63M | 110.00K | 54.00K | 2.80M | 3.30M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -460.00K | 1.47M | 27.00K | 69.00K | 52.00K | 28.00K | 20.00K | -13.00K | 40.98K | 1.63M | 558.00K | 0.00 | 0.00 | 0.00 | 11.57M | 797.00K | 400.00K | 400.00K | 153.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 100.22% | 99.93% | 96.43% | 100.00% | 100.00% | 96.55% | 86.96% | 216.67% | 99.96% | 68.72% | 59.49% | 0.00% | 0.00% | 0.00% | 194.71% | 87.87% | 88.11% | 12.51% | 4.43% | 0.00% | 0.00% | 0.00% |
| Research & Development | 31.00K | 30.00K | 30.00K | 38.00K | 35.00K | 38.00K | 43.00K | 443.00K | 578.00K | 278.00K | 113.00K | 99.00K | 158.00K | 64.00K | 0.00 | 10.39M | 20.95M | 10.87M | 7.54M | 12.80M | 11.10M | 13.16M | 11.05M |
| General & Administrative | 734.00K | 850.00K | 1.00M | 910.00K | 807.00K | 755.00K | 1.19M | 1.26M | 1.41M | 1.72M | 1.98M | 2.70M | 1.08M | 1.22M | 2.43M | 5.14M | 5.58M | 5.58M | 5.46M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.69M | 848.00K | -76.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 734.00K | 850.00K | 1.00M | 910.00K | 807.00K | 755.00K | 1.19M | 1.26M | 1.41M | 1.72M | 3.67M | 3.55M | 1.00M | 1.22M | 2.43M | 5.14M | 5.58M | 5.58M | 5.46M | 4.13M | 3.11M | 3.64M | 3.00M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 9.00K | 8.00K | 7.00K | 25.00K | 71.00K | -802.00K | 12.00K | -30.00K | -139.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -28.77M | 916.00K | 1.07M |
| Operating Expenses | 765.00K | 880.00K | 1.03M | 948.00K | 842.00K | 793.00K | 1.25M | 1.71M | 2.00M | 2.02M | 3.85M | 3.70M | 1.16M | 1.26M | 2.29M | 15.53M | 26.53M | 16.45M | 13.00M | 16.93M | -14.56M | 17.71M | 15.12M |
| Cost & Expenses | 765.00K | 880.00K | 1.03M | 948.00K | 842.00K | 793.00K | 1.25M | 1.71M | 2.00M | 2.02M | 4.59M | 4.08M | 1.16M | 1.26M | 2.29M | 15.53M | 26.64M | 16.50M | 15.79M | 20.23M | -14.56M | 17.71M | 15.12M |
| Interest Income | 36.00 | 36.00K | 8.00K | 33.00K | 93.00K | 87.00K | 16.00K | 0.00 | 0.00 | 10.00K | 10.00K | 43.00K | 45.00K | 2.00K | 3.00K | 317.00K | 668.00K | 1.06M | 503.00K | 352.00K | 352.00K | 0.00 | 0.00 |
| Interest Expense | 0.00 | 468.00K | 21.00K | 17.00K | 29.00K | 80.00K | 29.00K | 16.00K | 6.00K | 35.00K | 35.00K | 15.00K | 8.00K | 7.00K | 2.00K | 3.00K | 4.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.00K | 1.00K | 1.00K | 1.00K | 842.00K | 1.00K | 1.00K | 3.00K | 7.00K | 53.00K | 313.00K | 136.00K | 94.00K | 42.00K | 13.00K | 39.00K | 108.00K | 243.00K | 242.00K | 319.00K | 440.00K | 0.00 | 0.00 |
| EBITDA | -764.00K | -879.00K | -1.03M | -947.00K | 0.00 | -792.00K | -1.25M | -2.56M | -2.00M | -1.97M | -190.00K | -2.18M | -1.11M | -1.22M | 2.58M | -18.40M | -25.03M | -15.41M | -12.37M | -16.46M | 15.36M | -17.71M | -15.12M |
| EBITDA Ratio | 0.00% | 84.10% | -170.26% | -3,875.00% | -388.41% | -8,638.46% | -5,768.97% | -3,747.83% | 6,266.67% | -4,480.49% | -8.02% | -404.69% | 0.00% | 0.00% | 0.00% | -155.47% | -2,817.31% | -3,499.12% | -328.81% | -476.46% | 0.00% | 0.00% | 0.00% |
| Operating Income | -765.00K | -880.00K | -1.03M | -948.00K | -842.00K | -793.00K | -1.25M | -2.56M | -3.61M | -2.02M | -2.89M | -2.36M | -1.16M | -1.26M | 2.57M | -9.59M | -25.74M | -16.05M | -14.38M | -16.78M | 14.56M | -17.71M | -15.12M |
| Operating Income Ratio | 0.00% | 191.72% | -70.33% | -3,385.71% | -1,220.29% | -1,525.00% | -4,296.55% | -11,134.78% | 60,183.33% | -4,931.71% | -122.16% | -251.17% | 0.00% | 0.00% | 0.00% | -161.46% | -2,837.38% | -3,534.36% | -449.80% | -485.70% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.02M | -468.00K | 1.47M | -2.01M | -505.00K | 3.78M | 465.00K | 16.00K | -1.63M | -97.00K | -2.52M | 614.00K | 17.00K | -1.00K | -4.00K | 314.00K | 590.00K | 1.14M | -1.57M | 352.00K | -28.77M | 597.00K | 0.00 |
| Income Before Tax | -1.78M | -1.35M | 435.00K | -782.00K | -1.35M | 2.99M | -781.00K | -2.55M | -3.62M | -2.12M | -3.71M | -1.74M | -1.21M | -1.26M | 2.56M | -9.28M | -25.15M | -14.91M | -13.94M | -16.42M | -14.21M | -17.11M | 0.00 |
| Income Before Tax Ratio | 0.00% | 293.68% | 29.67% | -2,792.86% | -1,952.17% | 5,742.31% | -2,693.10% | -11,065.22% | 60,366.67% | -5,168.29% | -156.73% | -185.71% | 0.00% | 0.00% | 0.00% | -156.18% | -2,772.33% | -3,283.04% | -435.94% | -475.51% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 961.00K | -1.47M | -166.00K | -69.00K | -7.64M | -457.00K | 832.00K | 2.31M | 505.00K | 458.00K | -1.79M | -1.22M | -1.26M | -23.00K | -31.00K | -206.00K | 227.00K | 78.00K | 49.00K | 78.00K | 27.00K | 12.67M |
| Net Income | -1.78M | -2.31M | 1.90M | -616.00K | -1.28M | 2.99M | -781.00K | -2.55M | -4.31M | -2.53M | -2.48M | -1.39M | -1.21M | -1.26M | 2.59M | -9.25M | -24.94M | -15.13M | -14.02M | -16.47M | -14.29M | -17.14M | -12.67M |
| Net Income Ratio | 0.00% | 503.05% | 129.67% | -2,200.00% | -1,852.17% | 5,742.31% | -2,693.10% | -11,065.22% | 71,850.00% | -6,163.41% | -104.52% | -148.19% | 0.00% | 0.00% | 0.00% | -155.66% | -2,749.61% | -3,333.04% | -438.38% | -476.93% | 0.00% | 0.00% | 0.00% |
| EPS | 0.00 | -0.42 | 0.36 | -0.12 | -0.25 | 0.58 | -0.17 | -0.93 | -1.63 | -1.09 | -1.11 | -0.64 | -0.62 | -0.11 | 0.44 | -15.79 | -54.57 | -37.50 | -41.19 | -61.13 | -6.39 | -7.71 | -5.71 |
| EPS Diluted | 0.00 | -0.42 | 0.31 | -0.12 | -0.25 | 0.58 | -0.17 | -0.93 | -1.63 | -1.09 | -1.11 | -0.64 | -0.62 | -0.11 | 0.44 | -15.79 | -54.57 | -37.50 | -4.16 | -6.00 | -6.39 | -7.71 | -5.71 |
| Weighted Avg Shares Out | 544.95M | 5.45M | 5.32M | 5.14M | 5.14M | 5.14M | 4.70M | 2.74M | 2.64M | 2.31M | 2.24M | 2.18M | 1.94M | 11.34M | 5.86M | 585.54K | 456.99K | 403.48K | 340.25K | 269.46K | 2.23M | 2.22M | 2.22M |
| Weighted Avg Shares Out (Dil) | 544.91M | 5.45M | 6.16M | 5.14M | 5.14M | 5.14M | 4.70M | 2.74M | 2.64M | 2.31M | 2.24M | 2.18M | 1.94M | 11.34M | 5.88M | 585.54K | 456.99K | 403.48K | 3.37M | 2.75M | 2.23M | 2.22M | 2.22M |
XTL Completed the Acquisition of The Social Proxy and a Private Placement of $1.5 Million
expands its IP portfolio to AI Web Data The Social Proxy is a web data AI company developing and powering an IP based platform for AI & BI Applications at scale Completed a Private Placement of $1.5 Million RAMAT GAN,...
XTL Entered Definitive Agreement to Acquire The Social Proxy
expands its IP portfolio to AI Web Data The Social Proxy is a web data AI company developing and powering an IP based platform for AI & BI Applications at scale Secured $1.5 Million in a Private Placement RAMAT GAN,...
XTL To Aquire The Social Proxy
expands its IP portfolio to AI Web Data The Social Proxy is a web data AI company developing and powering an IP based platform for AI & BI Applications at scale Secured $1.5 Million in a Private Placement RAMAT GAN,...
XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Ramat Gan, Israel, Oct. 20, 2023 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical stage biopharmaceutical company whose main assets consists of an IP portfolio relating to hCDR1 for the treatment of...
XTL Biopharmaceuticals Confirms that it has not Experienced any Disruption to its Business Operations in Israel
Ramat Gan, Israel, Oct. 20, 2023 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical stage biopharmaceutical company whose main assets consists of an IP portfolio relating to hCDR1 for the treatment of...
Dr. Morris C. Laster Files Preliminary Proxy Statement Nominating Two Highly-Qualified Individuals For Election To Board At Scopus BioPharma Inc.'s 2021 Annual Meeting
JERUSALEM, Sept. 20, 2021 /PRNewswire/ -- Dr. Morris C.
XTLB Stock Price Increases Over 100% Pre-Market: Why It Happened
The stock price of XTL Biopharmaceuticals (NASDAQ: XTLB) has increased by over 100% pre-market. This is why it happened.
Source: https://incomestatements.info
Category: Stock Reports